128 related articles for article (PubMed ID: 7961118)
1. p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries.
Watanabe M; Ushijima T; Kakiuchi H; Shiraishi T; Yatani R; Shimazaki J; Kotake T; Sugimura T; Nagao M
Jpn J Cancer Res; 1994 Sep; 85(9):904-10. PubMed ID: 7961118
[TBL] [Abstract][Full Text] [Related]
2. Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries.
Watanabe M; Fukutome K; Shiraishi T; Murata M; Kawamura J; Shimazaki J; Kotake T; Yatani R
Carcinogenesis; 1997 Jul; 18(7):1355-8. PubMed ID: 9230279
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations occur in clinical, but not latent, human prostate carcinoma.
Konishi N; Hiasa Y; Hayashi I; Matsuda H; Tsuzuki T; Ming T; Kitahori Y; Shiraishi T; Yatani R; Shimazaki J
Jpn J Cancer Res; 1995 Jan; 86(1):57-63. PubMed ID: 7737911
[TBL] [Abstract][Full Text] [Related]
4. Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer.
Uchida T; Wada C; Shitara T; Egawa S; Koshiba K
Br J Cancer; 1993 Oct; 68(4):751-5. PubMed ID: 7691145
[TBL] [Abstract][Full Text] [Related]
5. APC gene mutations in human prostate cancer.
Watanabe M; Kakiuchi H; Kato H; Shiraishi T; Yatani R; Sugimura T; Nagao M
Jpn J Clin Oncol; 1996 Apr; 26(2):77-81. PubMed ID: 8609698
[TBL] [Abstract][Full Text] [Related]
6. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations.
Shiraishi T; Muneyuki T; Fukutome K; Ito H; Kotake T; Watanabe M; Yatani R
Anticancer Res; 1998; 18(4B):2789-92. PubMed ID: 9713462
[TBL] [Abstract][Full Text] [Related]
7. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer.
Suzuki H; Komiya A; Aida S; Ito H; Yatani R; Shimazaki J
Prostate; 1996 May; 28(5):318-24. PubMed ID: 8610059
[TBL] [Abstract][Full Text] [Related]
8. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
9. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
10. p53 in prostate cancer: frequent expressed transition mutations.
Chi SG; deVere White RW; Meyers FJ; Siders DB; Lee F; Gumerlock PH
J Natl Cancer Inst; 1994 Jun; 86(12):926-33. PubMed ID: 7515114
[TBL] [Abstract][Full Text] [Related]
11. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
12. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
Shi XB; Bodner SM; deVere White RW; Gumerlock PH
Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
[TBL] [Abstract][Full Text] [Related]
13. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
14. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan.
Sasa M; Kondo K; Komaki K; Uyama T; Morimoto T; Monden Y
Breast Cancer Res Treat; 1993 Sep; 27(3):247-52. PubMed ID: 8312582
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
16. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis.
Rakozy C; Grignon DJ; Li Y; Gheiler E; Gururajanna B; Pontes JE; Sakr W; Wood DP; Sarkar FH
Pathol Res Pract; 1999; 195(3):129-35. PubMed ID: 10220791
[TBL] [Abstract][Full Text] [Related]
17. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
18. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer.
Dinjens WN; van der Weiden MM; Schroeder FH; Bosman FT; Trapman J
Int J Cancer; 1994 Mar; 56(5):630-3. PubMed ID: 8314337
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations and overexpressions in Japanese breast cancer.
Fukushima T; Onda M; Abe R; Otake T; Kimijima I; Tsuchiya A
Eur J Surg Oncol; 1995 Dec; 21(6):595-600. PubMed ID: 8631401
[TBL] [Abstract][Full Text] [Related]
20. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
